Wilson Sonsini Goodrich & Rosati is advising K18 on the transaction. Unilever announced it signed an agreement to acquire premium biotech haircare brand K18. Founded in 2020...
Unilever’s Acquisition of K18
JURA Bio’s $16.1 Million Financing and Replay Collaboration
Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
Seal Rock Therapeutics’ Out-Licensing Agreement with GENFIT
Wilson Sonsini Goodrich & Rosati advised Seal Rock on the transaction. Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, has...
Gilead’s Acquisition of XinThera
Wilson Sonsini Goodrich & Rosati advised XinThera on the transaction. Gilead Sciences announced the acquisition of San Diego-based XinThera, a privately held biotech company. The acquisition...
Apexigen’s Business Combination Agreement with Brookline Capital Acquisition Corp.
Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...
Regor Therapeutics’ Collaboration with Lilly
Wilson Sonsini Goodrich & Rosati advised Regor Therapeutics on the deal. Eli Lilly and Company and Regor Therapeutics Group entered into a multi-year research collaboration and...
Arena Pharmaceuticals’ Strategic Collaboration with Aristea Therapeutics
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
Aristea’s $63 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...